Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 13, 2023 Post category:CD19/Scientific Publications Continue ReadingPoster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naïve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Poster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 12, 2023 Post category:CD19/Scientific Publications Continue ReadingPoster, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
Presentation, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Post author:andrewkaretas Post published:June 9, 2023 Post category:CD19/Scientific Publications Continue ReadingPresentation, Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)
TRAVERSE: A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) Post author:andrewkaretas Post published:April 6, 2023 Post category:CD70/Scientific Publications Continue ReadingTRAVERSE: A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Selective Targeting of Host CD70+ Alloreactive Cells With a CD70 Dagger™ Receptor to Prolong Allogeneic CAR T Cell Persistence Post author:andrewkaretas Post published:February 18, 2023 Post category:PLATFORM/Scientific Publications Continue ReadingSelective Targeting of Host CD70+ Alloreactive Cells With a CD70 Dagger™ Receptor to Prolong Allogeneic CAR T Cell Persistence
Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer Post author:andrewkaretas Post published:January 18, 2023 Post category:DLL3/Scientific Publications Continue ReadingAllogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
Allogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results Post author:andrewkaretas Post published:January 18, 2023 Post category:BCMA/Scientific Publications Continue ReadingAllogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results
Poster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Post author:andrewkaretas Post published:December 18, 2022 Post category:BCMA/Scientific Publications Continue ReadingPoster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Presentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Post author:andrewkaretas Post published:December 7, 2022 Post category:BCMA/Scientific Publications Continue ReadingPresentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Generation of Hypoimmunogenic Allogeneic CAR T Cells by Inactivation of Transcriptional Regulators of HLA Class I and II Genes Post author:andrewkaretas Post published:November 18, 2022 Post category:PLATFORM/Scientific Publications Continue ReadingGeneration of Hypoimmunogenic Allogeneic CAR T Cells by Inactivation of Transcriptional Regulators of HLA Class I and II Genes
